Tag: ATX
Amplia Therapeutics completes design of phase 2 AMP945 trial to treat advanced pancreatic cancer
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has completed the design for a phase 2 clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of advanced...
Amplia Therapeutics prepares for phase two AMP945 trial backed by shareholders
Amplia Therapeutics (ASX: ATX) will be spending the September quarter finalising the design of phase two clinical trials of its lead drug AMP945 in both pancreatic cancer and idiopathic lung fibrosis ...
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis.
...
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat pa...
Amplia Therapeutics receives second orphan drug designation for treatment of chronic lung disease
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received a second orphan drug designation from the US Food and Drug Administration for its focal adhesion kinase inhibitor AMP945.
The desi...
Amplia Therapeutics receives FDA orphan drug designation for pancreatic cancer
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received regulatory approval from the US Food and Drug Administration (FDA) for its Focal Adhesion Kinase inhibitor (FAKi) AMP945 – a novel ne...
